aromasil has been researched along with Breast Cancer, Male in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown-Glaberman, UA; Budd, GT; Burkard, ME; Connolly, RM; Faller, BA; Kaufman, PA; Lee, MJ; Levine, EG; Miller, KD; Onitilo, AA; Piekarz, RL; Royce, ME; Smith, KL; Sparano, JA; Thomas, A; Trepel, JB; Winn, JS; Wolff, AC; Zhao, F | 1 |
| Ballatore, Z; Battelli, N; Berardi, R; Cascinu, S; De Lisa, M; Pagliacci, A; Pistelli, M | 1 |
| Doyen, J; Ferrero, JM; Fontana, X; Italiano, A; Largillier, R; Thyss, A | 1 |
| Giordano, SH; Hortobagyi, GN | 1 |
| Amaddeo, P; Barbaglio, A; Faldi, F; Fontana, S; Ghilardi, R; Pericotti, S | 1 |
1 trial(s) available for aromasil and Breast Cancer, Male
| Article | Year |
|---|---|
E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzamides; Biomarkers, Tumor; Breast Neoplasms; Breast Neoplasms, Male; Double-Blind Method; Drug Administration Schedule; Female; Histone Deacetylase Inhibitors; Humans; Male; Middle Aged; Progression-Free Survival; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; South Africa; Time Factors; United States | 2021 |
4 other study(ies) available for aromasil and Breast Cancer, Male
| Article | Year |
|---|---|
Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report.
Topics: Adult; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms, Male; Cell Proliferation; Disease Progression; Disease-Free Survival; Estrogen Receptor alpha; Everolimus; Humans; Male; Prognosis; Receptor, ErbB-2; Receptors, Progesterone; Treatment Outcome | 2016 |
Aromatase inhibition in male breast cancer patients: biological and clinical implications.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms, Male; Carcinoma; Estradiol; Humans; Letrozole; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Retrospective Studies; Survival Analysis; Testosterone; Treatment Outcome; Triazoles | 2010 |
Leuprolide acetate plus aromatase inhibition for male breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Humans; Letrozole; Leuprolide; Lung Neoplasms; Lymphatic Metastasis; Male; Mastectomy, Modified Radical; Middle Aged; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Triazoles | 2006 |
Male breast cancer with mandibular metastasis. A case report.
Topics: Aged; Androstadienes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Cortisone; Cyclophosphamide; Diphosphonates; Docetaxel; Fatal Outcome; Fluorouracil; Furosemide; Humans; Imidazoles; Liver Neoplasms; Male; Mandibular Neoplasms; Mastectomy, Modified Radical; Methotrexate; Omeprazole; Osteolysis; Phenobarbital; Taxoids; Toremifene; Vinblastine; Vinorelbine; Zoledronic Acid | 2007 |